drugset / Trial / NCT07130617
Evaluation of the Efficacy and Safety of Megestrol Acetate in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the efficacy of Megestrol Acetate Oral Suspension in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy in Malignant Solid Tumor Patients
Timeline
- Start
- 2025-09-29
- Primary completion
- 2026-07-31
- Completion
- 2026-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Megestrol Acetate | Other / unclassified | 312.5 mg | Oral |
| Subject | Megestrol Acetate | Other / unclassified | 625 mg | Oral |
| Subject | Megestrol Acetate | Other / unclassified | 937.5 mg | Oral |
Indications
No indication recorded.